Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | PSMB5 | P28074 | 5/20 | 0.41 |
| ▸ | PSMB8 | P28062 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21836463 | 0.80 | MAOB (0.51) | MAOBCA2PSMB5PSMB8KDM4E | |
| SCHEMBL1027115 | 0.77 | KDM4E (0.62) | MAOBCA2PSMB5PSMB8KDM4E | |
| Ammonia Solution, Strong SCHEMBL6385399 | 0.76 | KDM4E (0.60) | MAOBCA2PSMB5PSMB8KDM4E | |
| SCHEMBL6511946 | 0.74 | MAOB (0.71) | MAOBCA2PSMB5PSMB8KDM4C | |
| SCHEMBL18331257 | 0.72 | MAOB (0.54) | MAOBCA2PSMB5PSMB8KDM4E | |
| SCHEMBL3147413 | 0.72 | MAOB (0.54) | MAOBCA2PSMB5PSMB8KDM4E | |
| SCHEMBL6511944 | 0.72 | MAOB (0.63) | MAOBCA2PSMB5PSMB8KDM4E | |
| SCHEMBL2092249 | 0.72 | MAOB (0.53) | MAOBCA2PSMB5PSMB8KDM4C | |
| SCHEMBL28840750 | 0.72 | MAOB (0.53) | MAOBCA2PSMB5PSMB8 | |
| SCHEMBL13749927 | 0.71 | CA2 (0.47) | MAOBCA2PSMB5PSMB8TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7837981-B2 | Methods for imaging soluble A-beta | GENERAL ELECTRIC COMPANY (US) | 2010-11-23 | — | — | US | disclosed |
| EP-1631561-B1 | COMPOSITIONS AND METHODS FOR NON-INVASIVE IMAGING OF SOLUBLE BETA-AMYLOID | GEN ELECTRIC (US) | 2010-08-18 | — | — | EP | disclosed |
| US-7727511-B2 | Agents for imaging soluble a-beta | GENERAL ELECTRIC COMPANY (US) | 2010-06-01 | — | — | US | disclosed |
| US-20070189967-A1 | AGENTS FOR IMAGING SOLUBLE A-BETA | GENERAL ELECTRIC COMPANY (US) | 2007-08-16 | — | — | US | disclosed |
| US-20070140960-A1 | METHODS FOR IMAGING SOLUBLE A-BETA | GENERAL ELECTRIC COMPANY (US) | 2007-06-21 | — | — | US | disclosed |
| EP-1631561-A2 | COMPOSITIONS AND METHODS FOR NON-INVASIVE IMAGING OF SOLUBLE BETA-AMYLOID | GENERAL ELECTRIC COMPANY (US) | 2006-03-08 | — | — | EP | disclosed |
| WO-2004100998-A2 | COMPOSITIONS AND METHODS FOR NON-INVASIVE IMAGING OF SOLUBLE BETA-AMYLOID | GENERAL ELECTRIC COMPANY (US) | 2004-11-25 | — | — | WO | disclosed |
| US-20040223909-A1 | Compositions and methods for non-invasive imaging of soluble beta-amyloid | GENERAL ELECTRIC COMPANY | 2004-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040223909-A1 | Compositions and methods for non-invasive imaging of soluble beta-amyloid | APP, APBA1, BACE1 | MAOB 886/4885CA2 2398/4885PSMB5 2332/4885 |
| US-20070140960-A1 | METHODS FOR IMAGING SOLUBLE A-BETA | APBA1, APP, FABP7 | MAOB 662/4885CA2 3370/4885PSMB5 2570/4885 |
| US-20070189967-A1 | AGENTS FOR IMAGING SOLUBLE A-BETA | APBA1, APP, FABP7 | MAOB 940/4885CA2 3234/4885PSMB5 2738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.